Session Information
Date: Thursday, June 8, 2017
Session Title: Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment
Session Time: 1:15pm-2:45pm
Location: Exhibit Hall C
Objective: To evaluate the relationship between non-motor symptom (NMS) severity, quality of life (QoL), and activities of daily living (ADL) in advanced Parkinson’s disease (PD) patients treated with levodopa-carbidopa intestinal gel (LCIG).
Background: LCIG, delivered via percutaneous gastrojejunostomy (PEG-J), improved NMS, QoL, and ADL in this study at 60 week follow-up.[ref1] However, the relationship between baseline and treatment-related changes in NMS severity and QoL in LCIG-treated advanced PD patients has not been reported.
Methods: NMS, QoL, and ADL were evaluated in advanced PD patients treated with LCIG during a 60-week, open-label Phase 3b study. Thirty-nine patients were enrolled and 28 completed the treatment. NMS were measured by the NMS Scale (NMSS) total and domain scores. The relationships between NMS severity and change from baseline to last visit in QoL (Parkinson’s Disease Questionnaire 39-item Summary Index [PDQ-39 SI] and ADL (Unified Parkinson’s Disease Rating Scale [UPDRS] part II score) were assessed using Pearson correlation coefficients.
Results: Baseline demographics were previously described for this study population.[ref1] While higher baseline NMSS total scores were associated with higher baseline PDQ-39 (r=0.38, P=0.019) and UPDRS II (r=0.34, P=0.043) scores, no significant correlations were observed between baseline NMS burden and change from baseline to last visit in PDQ-39 (r=-0.09, P=0.607) and UPDRS II (r=0.05, P=0.786) scores.[figure1] Changes from baseline to last visit in the NMSS total score and the mood/cognition and attention/memory domain scores were significantly correlated with QoL improvements (PDQ-39 SI) at last visit (NMSS total score: r=0.50, P=0.002; mood/cognition domain: r=0.46, P=0.005; attention/memory domain: r=0.45, P=0.005.[table1]
Conclusions: While baseline NMS severity was not associated with changes in QoL and ADL, improvements in NMSS total score and the attention/memory domain were strongly correlated with QoL improvements in LCIG-treated patients.
References: 1. Standaert et al. Mov Disord. 2015
To cite this abstract in AMA style:
D. Standaert, R. Rodriguez, J. Slevin, M. Lobatz, C. Hall, M. Facheris, J. Benesh, S. Dubow. Improvement in attention/memory domains in advanced Parkinson’s disease patients treated with levodopa-carbidopa intestinal gel is associated with better quality of life [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/improvement-in-attentionmemory-domains-in-advanced-parkinsons-disease-patients-treated-with-levodopa-carbidopa-intestinal-gel-is-associated-with-better-quality-of-life/. Accessed June 15, 2025.« Back to 2017 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/improvement-in-attentionmemory-domains-in-advanced-parkinsons-disease-patients-treated-with-levodopa-carbidopa-intestinal-gel-is-associated-with-better-quality-of-life/